

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVES**

The Board of Directors (the “**Board**”) of Ascletis Pharma Inc. (the “**Company**”) announces that Mr. Yim Lok Kwan (“**Mr. Yim**”) has tendered his resignation as the company secretary of the Company (the “**Company Secretary**”) and has ceased to act as an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and an authorised representative of the Company for accepting service of process or notice on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (collectively, the “**Authorised Representatives**”) with effect from August 22, 2022.

Mr. Yim has confirmed that he has no disagreement with the Board and that there are no circumstances relating to his resignation which needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Mr. Chung Ming Fai (“**Mr. Chung**”) has been appointed as the Company Secretary and Authorised Representatives with effect from August 22, 2022.

Mr. Chung is a vice president of SWCS Corporate Services Group (Hong Kong) Limited and has over 17 years of experience in corporate secretary, mergers and acquisitions, financial reporting and auditing. Mr. Chung is currently a fellow of the Hong Kong Institute of Certified Public Accountants and a member of CPA Australia. He obtained his bachelor’s degree in commerce from the Australian National University.

The Board would like to take this opportunity to express its gratitude to Mr. Yim for his contribution to the Company during his tenure of service and welcome Mr. Chung on his new appointment.

By order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People’s Republic of China  
August 22, 2022

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*